skip to primary navigationskip to content
 

Dr Walid Khaled

Dr Walid  Khaled

University Lecturer

Cellular and molecular characterization of breast cancer heterogeneity


Office Phone: +44 (0) 1223 3 34035 / Lab: 3 34029

Keywords

  • Cancer biology, Cancer therapeutics, Molecular biology, proteomics, genetic screens, Chip-seq.

Topics

  • Cancer and Infectious Diseases

Key Publications

Walid T. Khaled# and Pentao Liu. Cancer Mouse Models: Past, Present and Future. Seminars in Cell and Developmental Biology. 2014 (in press)

Yong Yu*, Juexuan Wang*, Walid T. Khaled*,Shannon Burke, Peng Li, Xiongfeng Chen, Wei Yang, Nancy Jenkins, Neal Copeland, Shujun Zhang and Pentao Liu. Bcl11a is essential for lymphoid development and negatively regulates p53. 2012 Journal of Experimental Medicine

Carrie O. Oliver*, Walid T. Khaled*, Hayley Frend, Jennifer Nichols and Christine J Watson The Stat6 regulated KRAB domain zinc finger protein Zfp157 regulates the balance of lineages in mammary gland and compensates for loss of Gata-3. Genes Dev. 2012 May 15;26(10):1086-97

Investigator biography

I read for my undergraduate degree at the University of Edinburgh followed by a Maters degree at Imperial College, London working with Prof. Eric Lam on the PI3K pathway and cell cycle regulation (2001-2002). I did my PhD training with Prof. Christine Watson, Department of Pathology, University of Cambridge where I focused on the role of Stat6 in mammary gland development (2002-2007). After my PhD, I was awarded a junior research fellowship at King's College, Cambridge (2008-2012). The fellowship allowed me to stay for a short post-doc with Prof. Watson during which I identified a novel cell fate regulator Zfp157 (2007-2009). In 2009 I joined the Sanger Institute to work with Dr. Pentao Liu. During my time at Sanger I worked on the connection between cell fate regulation and breast cancer development particularly focusing on the transcription regulator BCL11A. In October 2013, I was appointed as a University Lecturer and group leader at the Department of Pharmacology, University of Cambridge. In my group, I aim to establish a research programme focusing on the cellular and molecular characterisation of breast cancer heterogeneity and the development of novel methods for the treatment of breast cancer. I have also initiated a collaboration with Dr. Ewan St John Smith (Department of Pharmacology) to identify tumour suppressor genes in the naked mole-rat using CRISPR and piggybac genetic screening approaches.